Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IGF-methotrexate conjugate - IGF Oncology

Drug Profile

IGF-methotrexate conjugate - IGF Oncology

Alternative Names: 765-IGF-MTX; IGF-MTX; IGF/MTX; Insulin-like-growth-factor-methotrexate-conjugate

Latest Information Update: 22 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IGF Oncology
  • Developer IGF Oncology; University of Chicago
  • Class Antineoplastics; Benzamides; Drug conjugates; Glutamates; Growth factors; Peptides; Pterins; Small molecules; Somatomedins
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Myelodysplastic syndromes; Myeloid leukaemia
  • No development reported Solid tumours

Most Recent Events

  • 13 Jun 2022 IGF Oncology terminates a phase I/II trial in Myelodysplastic syndromes and Myeloid leukaemia (Late-stage disease, Second-line therapy or greater) in USA due to financial challenges of the sponsor (IV) (NCT03175978)
  • 01 Jul 2020 IGF Oncology suspends a phase I/II trial in Myelodysplastic syndromes (Late-stage disease, Second-line therapy or greater) in USA due to financial challenges of the sponsor (IV) (NCT03175978)
  • 28 Mar 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top